Analyses of Safety Profile and Homologous Antibody Responses to a Mammalian Cell-Based, MF59-Adjuvanted, A/H5N1, Pandemic Influenza Vaccine across Four Phase II/III Clinical Trials in Healthy Children, Adults, and Older Adults

Analyses of Safety Profile and Homologous Antibody Responses to a Mammalian Cell-Based, MF59-Adjuvanted, A/H5N1, Pandemic Influenza Vaccine across Four Phase II/III Clinical Trials in Healthy Children, Adults, and Older Adults

Modern cell culture-based technology eliminates vaccine manufactures reliance on embryonated chicken eggs, which may become compromised during an avian influenza pandemic. Four studies (total N = 6230) assessed the immunogenicity and safety of mammalian cell-based, MF59<sup>®</sup>-adjuv...

Full description

Bibliographic Details
Main Authors: Eve Versage, Esther van Twuijver, Wim Jansen, Ad Theeuwes, Daphne Sawlwin, Matthew Hohenboken
Format: Article
Language:English
Published: MDPI AG 2021-12-01
Series:Vaccines
Subjects:
influenza
vaccine
pandemic
cell culture
MF59
adjuvant
Online Access:https://www.mdpi.com/2076-393X/9/12/1468

Internet

https://www.mdpi.com/2076-393X/9/12/1468

Similar Items